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BACKGROUND. Based on the 1998 Patient Care Evaluation (PCE) from the American
College of Surgeons National Cancer Data Base (NCDB), the authors described
contemporary nationwide patterns of prostate carcinoma presentation, diagnosis,
and staging.
METHODS. The authors reviewed 54,212 cases from the 1998 PCE. Demographics,
presenting signs and symptoms, tumor characteristics, prostate biopsy techniques,
and use of staging modalities were evaluated.
RESULTS. The mean age of patients in the sample was 68 years. Among patients
with available data, 87.5% had a prostate specific antigen (PSA) level of 4 ng/mL or
higher, 83.1% had American Joint Committee on Cancer (AJCC) Stage I–II lesions,
80.2% had well or moderately differentiated cancers, and 68.7% of newly diagnosed
patients were asymptomatic. Compared with symptomatic patients, asymptomatic
patients were more likely to have localized disease (84.6% vs. 78.2%, P  0.01) and
well or moderately differentiated tumors (82.2% vs. 74.6%, P  0.01). Transrectal
ultrasound- guided prostate biopsy was the most common method of tissue
confirmation (45.4%). Radionuclide bone scintigraphy was the most frequently
employed staging modality (48.7%). Use of various staging evaluations was more
frequent among patients at increased risk for disseminated disease (PSA  10
ng/mL and/or high-grade tumors) versus patients at lower risk (PSA  10 and low
to moderate-grade tumors) for metastatic disease (P  0.005).
CONCLUSIONS. Most newly diagnosed patients with prostate carcinoma are asymp-
tomatic and have moderately differentiated and organ-confined disease. Com-
pared with symptomatic patients, tumors in asymptomatic men are associated
with lower pretreatment PSA levels, AJCC stage, and tumor grade. Selective use of
staging evaluations, based on risk of metastatic disease, may be relatively uncom-
mon. The NCDB remains a unique and rich source of novel patient care informa-
tion and serves as a national point of reference for prostate carcinoma presenta-
tion, diagnosis, and staging. Cancer 2003;98:1169 –78.
© 2003 American Cancer Society.
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The American College of Surgeons Commission on Cancer (CoC)National Cancer Data Base (NCDB) was established to evaluate
nationwide patterns of cancer presentation, care, and outcomes. Ear-
lier reports from the NCDB have provided a wealth of information
regarding prostate carcinoma diagnosis, staging, and therapy through
the middle of the last decade.1– 6 The prostate specific antigen (PSA)
era has been marked by a considerable shift in the number of incident
cases of prostate carcinoma, as well as a stage migration toward a
higher proportion of localized tumors.2,7 Moreover, the advent of PSA
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testing prompted the development of various guide-
lines for optimal screening of asymptomatic men and
staging of patients with newly diagnosed cancers.2,8
The current study reviews the findings from the 1998
NCDB prostate carcinoma Patient Care Evaluation
(PCE) and describes contemporary nationwide pat-
terns of presentation, diagnosis, and staging of ade-
nocarcinoma of the prostate. Unique to this report
from the NCDB is the availability of pretreatment PSA
levels and information on patient symptoms at the
time of presentation, particularly among African-
Americans and patients with a positive family history.
Also included in the current review is an evaluation of
prostate carcinoma staging practices in patients at
variable risk for metastatic disease.
MATERIALS AND METHODS
The NCDB is a joint endeavor of the CoC of the Amer-
ican College of Surgeons and the American Cancer
Society (ACS). Data from the NCDB have been com-
pared in a previous study with the population-based
Surveillance, Epidemiology and End Results (SEER)
registry and shown to be similar in terms of patient
and disease characteristics.9 NCDB data are collected
using a standardized, electronic data abstraction for-
mat that has been described previously.5–7
Sample and Population
In 1998, 1504 hospitals submitted data to the NCDB.
Of these, 66% (990 hospitals) participated in the pros-
tate carcinoma PCE. Individual hospital registries
were requested to provide demographic and clinico-
pathologic information on cases with histologically
proven prostate carcinoma that was diagnosed and/or
initially treated at their institution between January 1,
1998 and December 31, 1998. Therefore, these cases
represent a prospective convenience sample rather
than a statistical sample from a defined population.
Initially, 64,909 cases were entered into the study. Of
these, 7005 cases were ineligible because the date of
diagnosis was outside the stated study parameters or
because treatment was initiated at a facility other than
the reporting institution. An additional 1947 cases
were determined to be clinical duplicates or eligible
cases that were reported by more than one registry.
When this occurred, it is the protocol of the NCDB to
retain the case with more comprehensive clinical in-
formation and to exclude the other(s). Of the remain-
ing 55,957 cases, only those with an ICD-0-2 primary
site of C61.9 (prostate gland), histology code of 8140,
and behavior codes of 2 or 3 (adenocarcinoma in situ
and adenocarcinoma, not otherwise specified [NOS],
respectively) were retained for analysis, providing a
final study population of 54,212 cases.10 The number
of cases retained for analysis per participating hospital
ranged from 1 to 387, with the mean number of cases
per hospital equal to 55.
Variables and Procedures
When available, several baseline demographic and
clinical parameters were determined for each patient
including age, race, pretreatment serum PSA (ng/mL),
stage, and grade. Ethnic/racial categories in the regis-
try data include white, black, American Indian, Chi-
nese, Japanese, Filipino, Hawaiian, Puerto Rican, His-
panic, and other/unknown. For the current study,
white race includes Caucasians of non-Spanish origin,
whereas African-American comprises all patients re-
ported as black.
The study utilized the American Joint Committee
on Cancer (AJCC) staging system.2,11 The AJCC stage
data represents a “best” staging system whereby the
reported stage is the pathologic stage whenever this
was available and clinical stage (about 56% of cases)
when the former was unavailable. Therefore, patho-
logic stage, when available, is provided to the exclu-
sion of clinical stage. This system is consistent with
previous NCDB reports.2,7
Descriptions of histologic grade have been de-
scribed in previous reports from the NCDB.2,7 Differ-
entiation between biopsy and prostatectomy tumor
grade was not captured as part of the study design.
The study design explicitly requested documenta-
tion of the presence or absence of specific, relevant
symptoms (low back pain, hematuria, and/or diffi-
culty with urination) at the time of initial diagnosis.
This allowed classification of cases as asymptomatic
(i.e., detected by abnormal PSA and/or digital rectal
examination [DRE]) or symptomatic (regardless of PSA
and/or DRE findings). Various techniques for tissue
confirmation of prostate carcinoma (e.g., transrectal
ultrasound-guided biopsy [TRUS], needle biopsy NOS,
perineal biopsy, transurethral resection [TURP], digi-
tal biopsy, and cytology) were abstracted explicitly
from the medical record. The utilization of prostate
carcinoma staging modalities is also characterized,
including radionuclide bone scans, computed tomog-
raphy (CT) scans of the abdomen and/or pelvis, mag-
netic resonance imaging (MRI) scans, and pelvic
lymph node dissection. For each staging modality, we
determined the proportion of patients with results
suggestive for tumor dissemination. In addition, pa-
tients were stratified, using pretreatment PSA and tu-
mor grade, into high-risk (PSA level  10 ng/mL
and/or poorly differentiated [Grades 3 and 4] cancers),
and low-risk (PSA  10 ng/mL and well or moderately
differentiated [Grades 1 and 2] cancers) groups based
on their likelihood of having extraprostatic disease at
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the time of diagnosis. This risk stratification allowed
analysis of staging evaluations in the context of re-
cently published practice guidelines.12,13
Descriptive statistics were used to evaluate the
frequencies, percentages, measures of central tenden-
cies, and variation. Given the large number of cases
included in these analyses, statistically significant dif-
ferences might result even in comparisons with clini-
cally insignificant differences. Therefore, formal tests
of comparisons were limited to specific situations for
which we had a priori hypotheses. For these analyses,
differences in proportion were evaluated using the
chi-square test at a significance level of 5%. Statistical
analyses were conducted using SPSS version 10 soft-
ware (SPSS, San Diego, CA).
RESULTS
Patient Characteristics
Demographic data for patents included in the 1998
PCE are provided in Table 1. The mean age for men
included in the 1998 analysis was 68.0  8.8 years. In
this cohort of patients, 32.9% of patients were younger
than 65 years of age, 1.9% of patients were younger
than 50 years of age, 8.4% were older than 80 years of
age, 12.6% of patients were African-American, and
15.4% had a family history of prostate carcinoma.
Tumor Characteristics
Pretreatment PSA levels were available for 61.2% of
cases and are summarized in Table 2. Among patients
with available data, 87.5% had a PSA level equal to or
greater than 4 ng/mL at the time of diagnosis.
AJCC stage was available for 94.9% of patients in
1998 (Table 2). The majority of patients (83.1%) had
localized prostate carcinoma (AJCC Stage I–II) and
only 6.4% of men had documentation of advanced
disease (AJCC Stage IV).
The proportion of patients with well differentiated
tumors was only 9.3%, whereas 70.9% of cases were
moderately differentiated (Table 2). Poorly and undif-
ferentiated grades were documented in 19.8% of cases.
Prostate Carcinoma Presentation
Overall, 68.7% of cases were diagnosed in the absence
of symptoms, including low back pain, hematuria,
and/or difficulty with urination. In addition, 97.8% of
asymptomatic patients had abnormal PSA values, ir-
respective of findings on DRE (Table 3). In terms of
tumor characteristics, asymptomatic patients were
more likely than symptomatic patients to have local-
ized disease (84.6% vs. 78.2%, P  0.01) and well or
moderately differentiated tumors (82.2% vs. 74.6%, P
 0.01). Moreover, 60% of asymptomatic patients with
prostate carcinoma had pretreatment PSA levels less
than 10 ng/mL compared with only 49.1% of symp-
tomatic patients. Table 4 summarizes the distribution
of asymptomatic and symptomatic patients stratified
by age at diagnosis, race, prostate carcinoma family
history, and type of health care coverage. In general,
TABLE 1
Demographic Characteristics of Men Entered into the 1998 Patient
Care Evaluation Study
Characteristics No. of subjects % of subjects
Patient age (yrs) n  54,188 (99.9%)a
Mean age (SD) 67.99 (8.82)




 80 4550 8.4
Race n  53,340 (98.4%)a
White 43,675 80.9
Black 6736 12.6
Other race 2929 5.5
Family history of prostate carcinoma n  38,341 (70.7%)a
None 32,430 84.6
Affected, first-degree relative 5173 13.5
Affected, non–first-degree relative 536 1.4
Affected, unknown relationship 202 0.5
SD: standard deviation.
a Total number of cases in the 1998 Patient Care Evaluation is 54,212. Discrepancy represents missing
or unknown data points.
TABLE 2
Pretreatment Prostate Specific Antigen, American Joint Committee
on Cancer Stage (1997 Classification), and Tumor Grade
Characteristics No. of subjects % of subjects
Pretreatment PSA (ng/mL) n  33,179 (61.2%)a
 4 4145 12.5
4–10 17,537 52.9
10.1–20 6225 18.8
 20 5272 15.9





Tumor grade n  51,322 (94.7%)b
1 (well differentiated) 4763 9.3
2 (moderately differentiated) 36,382 70.9
3 (poorly differentiated) 9978 19.4
4 (undifferentiated) 199 0.4
PSA: prostate specific antigen; AJCC: American Joint Committee on Cancer.
a The results from two of the commercial registry software vendors that support the National Cancer
Data Base were excluded for technical reasons. As a result, specific pretreatment prostate specific
antigen values are reported for only 33,179 cases.
b Total number of cases is 54,212. Discrepancy represents missing or unknown data points.
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the proportion of asymptomatic patients with prostate
carcinoma was higher among younger men, with ab-
normalities of PSA and/or DRE responsible for the
diagnosis in nearly 78% of patients younger than 60
years of age. Asymptomatic patients were slightly
more prevalent among white men (69.3%) than among
African-American men (66.3%). Among patients with
and without a family history of prostate carcinoma,
70.3% and 69.6% of newly diagnosed patients were
asymptomatic, respectively. The mean age at diagno-
sis was younger among both asymptomatic African-
American patients (65.5 years vs. 67.0 years for whites)
and asymptomatic patients with a positive family his-
tory (65.2 years vs. 67.1 years for a negative family
history).
Tissue Confirmation and Staging
The prostate biopsy techniques utilized in 1998 are
summarized in Table 5. Needle biopsy, defined as all
biopsy modalities other than TURP, was the most
common method of tissue diagnosis (80.1%). At least
45.4% of biopsies were performed with TRUS guid-
ance. In 4.2% of patients, digitally guided transrectal
biopsy was performed for tissue confirmation. Twenty
percent of patients were diagnosed by TURP.
Radionuclide bone scintigraphy was the most fre-
quently employed staging modality, with 26,420
(48.7%) studies performed. Among patients who un-
derwent a bone scan, 13% were positive for evidence
of metastatic disease. CT scans were employed fre-
quently, including pelvic CT scans in 30.5% of cases
and abdominal CT scans in 28.9% of cases. Table 6
summarizes the utilization of prostate carcinoma stag-
ing modalities stratified by risk of metastatic disease.
Among patients with complete data, 67.4% were clas-
sified as low risk and 37.6% as high risk for metastatic
disease. For each staging modality, the proportion of
patients undergoing evaluation was significantly
higher among patients at high risk for metastatic dis-
ease (all P values  0.005). Regardless of staging mo-
dality, the proportion of patients who had positive
tests was significantly higher among patients at high
risk for metastatic disease (all P values  0.001).
DISCUSSION
The PCE study of prostate carcinoma provides impor-
tant insight into contemporary prostate carcinoma
presentation, diagnosis, and staging based on a na-
tionwide sample of patients that includes about 40%
of incident cases. Greater than 1500 hospitals contrib-
uted to the study, including community and academic
medical centers from all geographic regions of the U.S.
The data may be considered a national point of refer-
ence for prostate carcinoma care during the corre-
sponding period of time.
The mean age at diagnosis (68.0  8.8 years) for
men with prostate carcinoma has decreased slightly,
when compared with reports from 1995 (68.8 years)
and 1992 (70.7 years).2,5 This age trend has been par-
alleled by a migration toward a higher proportion of
localized tumors of low and/or moderate grade.1,4 –7
Furthermore, this migration has been attributed pri-
marily to the impact of widespread prostate carci-
noma screening initiatives.14,15–19 To date, however,
efforts to validate, on a national level, the associations
between screening and stage/grade migration have
been limited to large screening studies that lacked
comparable control groups.
The PCE study addressed this limitation through
explicit documentation of tumor characteristics, pre-
treatment PSA levels, and presenting symptoms. The
majority (68.7%) of patients with cancers character-
ized by the 1998 PCE were asymptomatic. Nearly all
(97.8%) asymptomatic men with prostate carcinoma
had an abnormal PSA level at the time of diagnosis.
Among asymptomatic patients, isolated DRE abnor-
malities were exceedingly rare (2.2%). It is reasonable
to speculate that most, if not all, asymptomatic pa-
tients were detected as a result of PSA-based prostate
carcinoma screening initiatives. Therefore, the 1998
TABLE 3
Summary of Contemporary Prostate Carcinoma Diagnosis Based on Prostate Specific Antigen, Digital Rectal Examination, and Clinical
Symptomsa
Characteristics
Abnormal PSA and abnormal
DRE (18,755, 48.6%)
Abnormal PSA and normal
DRE (18,544, 48.1%)
Normal PSA and abnormal
DRE (1252, 3.2%) Tumors (%)
Asymptomatic 12,536 (32.5%) 13,363 (34.7%) 588 (1.5%) 68.7a
At least one symptom 6219 (16.1%) 5181 (13.4%) 664 (1.7%) 31.3
PSA: prostate specific antigen; DRE: digital rectal examination.
a Summary of all patients (n  38,551) whose pretreatment prostate specific antigen ( 4 ng/dL) or digital rectal examination is documented as abnormal. Based on the data abstraction instrument, it was possible
to confirm that pretreatment prostate specific antigen was abnormal without having the actual value of the prostate specific antigen level. Patients for whom data on prostate specific antigen, digital rectal
examination, or clinical symptoms were incomplete were excluded from this analysis.
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PCE may provide novel insight into the current status
of prostate carcinoma screening in the U.S.
It is has been proposed that screening based on
PSA is associated with a higher proportion of clinically
and pathologically localized tumors.14,15,17,18 A recent
analysis compared the pathologic stage and grade of
tumors detected by PSA-based screening to historical
cancers detected by needle biopsy or TURP.19 The
authors found that screen-detected cancers were
more likely to be pathologically organ confined and
TABLE 4







abnormal DRE (%) Tumors (%)
Age (yrs)
 50 (n  758)
Asymptomatic 269 (35.5) 305 (40.2) 16 (2.1) 77.8
At least one symptom 89 (11.7) 73 (9.6) 6 (.8) 22.2
50–59 (n  5987)
Asymptomatic 2126 (35.5) 2407 (40.2) 96 (1.6) 77.3
At least one symptom 679 (11.3) 633 (10.6) 46 (0.8) 22.7
60–69 (n  14,810)
Asymptomatic 5032 (34.0) 5447 (36.8) 216 (1.4) 72.2
At least one symptom 2173 (14.7) 1784 (12.0) 158 (1.0) 27.8
70–79 (n  14,120)
Asymptomatic 4462 (31.6) 4583 (32.5) 217 (1.5) 65.6
At least one symptom 2517 (17.8) 2065 (14.6) 276 (2.0) 34.4
 80 (n  2860)
Asymptomatic 645 (22.6) 616 (21.5) 42 (1.5) 45.6
At least one symptom 757 (26.5) 622 (21.7) 178 (6.2) 54.4
Race
White (n  31,233)
Asymptomatic 10,431 (33.4) 10,701 (34.3) 514 (1.6) 69.3
At least one symptom 5015 (16.1) 4025 (12.9) 548 (1.8) 30.7
Black (n  4771)
Asymptomatic 1293 (27.1) 1822 (38.1) 49 (1.0) 66.3
At least one symptom 764 (16.0) 779 (16.3) 64 (1.3) 33.7
Other race (n  1997)
Asymptomatic 632 (31.6) 629 (31.5) 20 (1.0) 64.1
At least one symptom 362 (18.1) 309 (15.5) 45 (2.3) 35.9
Family history
Negative family history (n  24,105)
Asymptomatic 8064 (33.5) 8372 (34.7) 337 (1.4) 69.6
At least one symptom 3860 (16.0) 3095 (12.8) 377 (1.6) 30.4
Positive family history (n  5065)
Asymptomatic 1803 (35.6) 1692 (33.4) 65 (1.3) 70.3
At least one symptom 832 (16.4) 631 (12.5) 42 (0.8) 29.7
Primary insurance
Private insurance (n  6400)
Asymptomatic 2215 (34.6) 2450 (38.3) 87 (1.4) 74.3
At least one symptom 840 (13.1) 736 (11.5) 72 (1.1) 25.7
Managed care (n  9477)
Asymptomatic 3427 (36.2) 3559 (37.6) 145 (1.5) 75.2
At least one symptom 1218 (12.9) 1034 (10.9) 94 (1.0) 24.8
Medicare (n  18,639)
Asymptomatic 5677 (30.5) 6117 (32.8) 258 (1.4) 64.7
At least one symptom 3286 (17.6) 2856 (15.3) 445 (2.4) 35.3
Veterans Administration (n  2300)
Asymptomatic 712 (31.0) 687 (29.9) 10 (0.4) 61.3
At least one symptom 572 (24.9) 296 (12.9) 23 (1.0) 38.7
PSA: prostate specific antigen; DRE: digital rectal examination
a Summary of results for patients for whom data on pretreatment prostate specific antigen, digital rectal examination, clinical symptoms, and relevant covariates (i.e., age, race, family history, insurance) were
complete.
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less likely to be Gleason score 8 –10 tumors. Nonethe-
less, a perennial limitation of such investigations is the
need for historical comparisons, rather than assess-
ment of a concurrent population of cancers detected
for indications other than screening based on PSA
levels. In contrast, the 1998 PCE identifies a large,
contemporary sample of patients with pertinent
symptoms (difficulty urinating, low back pain, and/or
hematuria) at the time of prostate carcinoma diagno-
sis, thereby providing a more valid control group.
Overall, 31.3% of patients reported one or more symp-
toms at the time of diagnosis. Despite the high prev-
alence of PSA abnormalities (95%) in these patients, it
seems reasonable to contend that the presence of
symptoms disqualifies PSA as a screening tool in these
patients.
Therefore, this is the first national study to allow
coincident comparison of asymptomatic patients and
patients with clinically diagnosed tumors and pro-
vides the first nationwide data supporting an associa-
tion between asymptomatic (screen detected) patients
and favorable stage and grade migrations. These ob-
servations are consistent with recent data from the
European Randomized Study of Screening for Prostate
Cancer.20 The European study demonstrated more fa-
vorable stage and grade outcomes among screen-de-
tected versus clinically diagnosed prostate carcino-
mas. If, as suggested by several investigators,
treatment of organ-confined cancers ultimately man-
ifests a survival benefit, then these findings may lend
additional credence to the premise that screening will
ultimately decrease prostate carcinoma mortality.17,18,21–24
These data also allow novel observations regard-
ing nationwide patterns of prostate carcinoma screen-
ing in the context of age, race, family history, and
health care insurance. Current recommendations for
prostate carcinoma screening vary between different
medical specialties and professional organiza-
tions.12,25 The ACS and the American Urological Asso-
ciation (AUA) continue to recommend screening with
PSA and DRE for all men older than 50 years of age,
whose life expectancy is at least 10 years. Initiation of
screening at a younger age (40 – 45 years) is advocated
for patients at increased risk, including African-Amer-
ican males and patients with a first-degree relative
diagnosed with prostate carcinoma. We observed that
greater than 70% of men younger than 70 years of age
were asymptomatic. This proportion decreased to
65.6% in the 70 –79-year-old age group and declined
further to 45.6% among men older than 80 years of
age. Although the prevalence of asymptomatic pa-
tients is higher among younger men who are more
likely, on average, to benefit from early detection, it is
noteworthy that among men 80 years and older,
nearly one-half of men were asymptomatic and, there-
fore, prostate carcinoma was likely to be detected by
screening. This finding is plausible in light of reports
describing contemporary practice patterns of both
urologists and primary care physicians, many of
whom continue routine PSA testing in patients older
than 80 years of age.26,27
Both the ACS and the AUA advocate commence-
ment of screening at a younger age among African-
American men and patients with a positive family
history. In the 1998 PCE, the proportion of asymptom-
atic men with prostate carcinoma was similar among
African-Americans (66.3%) and whites (69.3%). How-
ever, the mean age at diagnosis was slightly younger
for asymptomatic black men (age 65.5 years vs. age 67
years). Although this finding suggests an important
trend toward earlier diagnosis of cancers in asymp-
tomatic blacks, the results of two recently published
studies comparing blacks and whites with screen-de-
tected cancers fail to support this hypothesis.28,29 Sim-
ilarly, patients with a positive family history were
younger (65.0 years) at the time of diagnosis than
patients with no affected relatives (67.1 years), al-
though the proportion of asymptomatic patients was
similar for these two groups (70.3% vs. 69.6%).
In terms of insurance coverage, the highest pro-
portions of asymptomatic men were detected among
patients enrolled in managed care plans and among
those with private health insurance. This finding is
consistent with a greater emphasis on preventative
health measures among commercial insurance plans
versus Medicare and/or Veterans Administration cov-
erage.
The results of the current study suggest a central
role for PSA-based screening in the contemporary di-
agnosis of prostate carcinoma. However, significant
controversy remains regarding the clinical signifi-
cance of tumors detected by screening initia-
tives.16,17,30 Several clinicopathologic parameters in-
TABLE 5
Distribution of Prostate Biopsy Modalities
Characteristics No. of subjects Subjects (%)
Biopsy modality (n  45,816, 84.5%)
TRUS biopsy 20,816 45.4
TURP 9117 19.9
Needle biopsy, NOS 6508 14.2
Digital transrectal biopsy 1917 4.2
Perineal biopsy 379 0.8
Cytology 118 0.3
Combination 2659 5.8
Biopsy, NOS 4302 9.4
TRUS: transrectal ultrasound; TURP: transurethral resection; NOS: not otherwise specified.
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cluding serum PSA levels, histologic grade, and tumor
stage have been reported to correlate with the biologic
aggressiveness of individual prostate carcino-
mas.25,31–35 Among patients with comprehensive data,
68.7% of reported cancers were found in asymptom-
atic patients and, thus, ostensibly detected by screen-
ing with either PSA and/or DRE. As a result, assess-
ment of the PSA levels and histologic grades of
asymptomatic (screen-detected) patients with pros-
tate carcinoma may provide insight regarding their
clinical significance. In terms of grade, 92.4% of
asymptomatic patients had tumors that were moder-
ately (Grade 2), poorly (Grade 3), or undifferentiated
(Grade 4) and were therefore associated with greater
biologic aggressiveness.36 In addition, 88% of asymp-
tomatic patients had PSA levels equal to or greater
than 4 ng/mL, a finding typically associated with more
clinically significant cancers, as well as a greater like-
lihood of extraprostatic extension.30 Furthermore, PSA
levels higher than 20 ng/mL were detected in 15.3% of
asymptomatic patients. This degree of PSA elevation
has been associated with an 80% risk of non– organ-
confined disease and at least a 15% chance of tumor
involvement of the seminal vesicles or pelvic lymph
nodes.30 In this context, the PSA and grade data sug-
gest that many of the asymptomatic cases from the
1998 PCE are clinically significant lesions based on
their potential for biologic aggressiveness.
Data from the 1998 PCE allow several observa-
tions regarding contemporary prostate biopsy tech-
niques. The current standard for prostate carcinoma
pathologic diagnosis is TRUS-guided needle biopsy of
the prostate .37 In 1998, only 45.4% of reported pa-
tients underwent TRUS-guided biopsy for pathologic
diagnosis. An additional 14.2% of patients underwent
prostate needle biopsy. However, for these patients,
explicit documentation regarding utilization of radio-
graphic guidance is not available. TURP (19.8%) re-
mains a common alternative method of tissue diagno-
sis. Overall, a significant number of patients may be
obtaining a tissue diagnosis by techniques other than
TRUS-guided biopsy and further studies and/or re-
finement of the PCE data abstraction tool may be
necessary to clarify the indications for these alterna-
tive approaches. As current trends in prostate biopsy
evolve, explicit evaluation of the number and location
of prostate biopsy cores, the percent of cancer in each
core, as well as the use of local anesthetic will enhance
the relevance of future patient care evaluations.37,38
In addition to patterns of diagnosis, data from the
1998 PCE also characterize contemporary utilization
of prostate carcinoma staging modalities. In 1998, the
most commonly employed staging modality was ra-
dionuclide bone scan in about 48.7% of patients. In
addition, nearly 30% of patients underwent staging CT
and/or pelvic lymphadenectomy. Although the utili-
zation of these staging modalities was relatively fre-
quent, the yield was fairly low. For each staging mo-
dality, with the exception of MRI scans, less than one
in three patients evaluated had abnormal findings
suggestive of cancer.
The utilization of staging evaluations was evalu-
ated in the context of disease risk to determine base-
line estimates of nationwide staging practices before
the publication and dissemination of formal guide-
lines.12,13,25 Our findings were somewhat encouraging,
in that, for each staging modality, the proportion of
patients tested, as well as the proportion of positive
tests, was uniformly greater in the high-risk group
(Table 6). However, radiographic and/or surgical stag-
ing of high-risk patients was not universal. In addition,
a significant proportion of patients in the low-risk
group may have undergone unnecessary staging eval-
uations. Nearly one-half of the low-risk patients re-
TABLE 6
Diagnostic Modalities for Evaluating Extent of Disease Stratified by Pretreatment Prostate Specific Antigen and Tumor Grade
PSA and grade criteria Bone scan CT of the abdomen CT of the pelvis MRI PLND
Low-risk category (21,063, 67.4)
PSA  10 ng/mL and low–moderate grade 10,047a 5108a 6272a 872a 5473a
47.7b 24.3b 29.8b 4.1b 26.0b
7.9c 11.5c 17.9c 50.5c 9.4c
High-risk category (10,177, 32.6)
PSA  10 ng/mL and/or high grade 6132a 3389a 3567a 700a 2802a
60.4b 33.4b 35.2b 6.9b 27.6b
21.7c 31.0c 33.2c 72.3c 35.9c
PSA: prostate specific antigen; CT: computed tomography; MRI: magnetic resonance imaging; PLND: pelvic lymph node dissection.
a Number of studies.
b Percentage of cases with test performed.
c Percent positive.
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ceived bone scans and approximately one-third un-
derwent cross-sectional imaging. Although the
potential for mitigating clinical circumstances is ac-
knowledged, strict adherence to recently published
guidelines would render most of these staging evalu-
ations unnecessary.12,13,25 This observation is consis-
tent with a recent update from the CaPSURE database
that evaluated the use of staging modalities with even
greater resolution.39 In that study, the investigators
used PSA, Gleason sum, and clinical stage to classify
patients into low, intermediate, and high-risk groups
for analysis of imaging test utilization. Similar to these
results, the authors concluded that although staging is
more frequent among high- risk cases, it is not per-
formed uniformly. Similarly, many patients at low and
intermediate risk for metastatic disease underwent
unnecessary testing.39 Therefore, nonselective staging
practices may be a persistent dilemma among urolo-
gists.40 An explanation for this finding is not readily
apparent and certainly merits evaluation in future
studies.
Although the findings from the current study pro-
vide an important characterization of contemporary
approaches to prostate carcinoma diagnosis and stag-
ing, there are several limitations of these data that
merit discussion. Although the NCDB represents a
large, nationwide sample, including both community
and academic medical centers, the enormous volume
of data in this repository precludes audit and verifica-
tion of all reports. Therefore, a finite number of data
errors are unavoidable. In addition, the selection of
hospitals for the NCDB is not based on systematic
sampling. Therefore, a perennial limitation of this data
set is the underrepresentation of diagnostic and treat-
ment encounters occurring outside the hospital set-
ting. In this framework, however, the study still eval-
uated approximately 40% of incident cases of prostate
carcinoma. Despite these limitations, prostate carci-
noma data from the NCDB has been compared with
population-based information from the SEER pro-
gram and has been shown to be similar, further estab-
lishing its role as a national point of reference.
Another limitation includes the use of the com-
bined staging system. In this context, the risk of un-
derstaging is potentially significant because the true
extent of disease is uncertain except among patients
treated with radical prostatectomy. However, the uni-
form application of this staging system across differ-
ent regions and patient populations may limit its im-
pact on the validity of our observations. Similar
concerns may be raised for the grading system, includ-
ing the use of a combination of biopsy and prostatec-
tomy tumor grades. The reported observations may be
limited by the absence of Gleason sum as the primary
grading system, given the prevalence of this classifi-
cation in contemporary prostate carcinoma research
and clinical practice. Nonetheless, the grading system
in the PCE study is similar to that utilized in previous
reports from the NCDB and therefore provides a basis
for comparative analyses. This analysis may also be
criticized for equating asymptomatic tumors (associ-
ated with abnormalities of PSA and/or DRE) with
screen-detected lesions. However, although the 1998
PCE provides no explicit data concerning the use of
screening, one may reasonably infer that the diagnosis
of prostate carcinoma in an asymptomatic patient
with an elevated PSA level and/or abnormal DRE was
prompted by one or both of these screening modali-
ties. In addition, we recognize that the observations
regarding prostate carcinoma screening are limited by
a lack of data regarding the number of men who were
screened and did not have cancer. Finally, this analy-
sis does not address treatment patterns or survival
among this patient cohort. The absence of these data
limits the significance of the observed association be-
tween asymptomatic cancers and lower stage and
grade. In other words, this finding has little clinical
value in the absence of appropriate therapeutic inter-
vention. Fortunately, corresponding treatment data
are available for this patient population and will be
described in pending communications from the
NCDB. Ultimately, data from established randomized,
controlled trials of prostate carcinoma screening will
provide the strongest evidence for an impact of
screening on mortality.41,42 Once survival data are
available for this cohort of patients in 2003, correlation
of survival outcomes among symptomatic versus
asymptomatic cancers may provide preliminary in-
sight on the nationwide impact of screening on mor-
tality from prostate carcinoma.
Conclusions
In 1998, most newly diagnosed prostate carcinomas
were of localized stage and moderate grade. A high
proportion of tumors were detected in asymptomatic
men with elevated PSA levels and/or abnormal find-
ings on DRE, suggesting a principal role for prostate
carcinoma screening. Asymptomatic cancers were di-
agnosed at a younger age in African-American men
and in men with a pertinent family history, potentially
reflecting adherence with current guidelines for pros-
tate carcinoma screening. Compared with symptom-
atic patients, cancers in asymptomatic men were
more likely to be organ confined and well or moder-
ately differentiated. This finding provides the first
demonstration, in a nationwide sample, of favorable
stage and grade outcomes among screened versus
symptomatic patients, diagnosed in the same time
1176 CANCER September 15, 2003 / Volume 98 / Number 6
interval. Whether these findings reflect a potential sur-
vival benefit will require future correlation with, as yet
unavailable, mortality data.
TRUS-guided prostate biopsy is the most com-
mon method of pathologic diagnosis, although utili-
zation of this technique is certainly not universal. Al-
though radiologic and surgical staging is more
common among patients at increased risk for extra-
prostatic disease, a substantial fraction of high-risk
patients may not receive sufficient evaluation of their
disease burden. In addition, more selective use of
staging studies among patients at low risk for dissem-
inated disease is desirable. The observations in the
current study provide a national point of reference for
evaluating current methods of prostate carcinoma di-
agnosis and staging.
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